Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins

An isolated polypeptide selected from the group consisting of:

• a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO:
• 100-245 ;
• or
• b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:
• 1-99.

A method for diagnosing or monitoring the presence and metastases of ovarian cancer in a patient, comprising the steps of:

• a) determining an amount of:
• (i) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO:
• 100-245;
• (ii) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:
• 1-99;
• (iii) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (i) or (ii);
• (iv) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (i) or (ii);
• (v) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO:
• 100-245;
• or
• (vi) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:
• 1-99 and;
• b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the ovarian specific marker in a normal control;
• wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of ovarian cancer.